2020 ACSoMP recommendations

Overview

ACSoMP was established in 2003 to provide advice to WHO, including its Collaborating Centre for International Drug Monitoring (the UMC), and through it to the Member States of WHO, on safety issues relating to medicinal products. It guides WHO on general and specific issues related to Pharmacovigilance (PV). The Committee is composed of 12 members drawn from the WHO Expert Advisory Panels for Drug Evaluation and for Drug Policies and Management and, where appropriate, in consultation with other relevant WHO clusters and expert advisory panels. ACSoMP meets once a year to discuss ongoing and new pharmacovigilance topics, with particular focus on issues related to public health programmes.